Why Alnylam Pharmaceuticals Is Crashing Today

Why Alnylam Pharmaceuticals Is Crashing Today
·2 min read

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were tanking on Thursday after the company reported its earnings results for the third quarter. The biopharmaceutical company's stock is down 14.1% as of 1:34 p.m. EDT, likely due to the company missing revenue estimates for the quarter. The company also announced its CEO, John Maraganore, will be retiring at the end of 2021.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting